Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience
Intra-Cellular Therapies Inc. (ITCI)
Last intra-cellular therapies inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intracellulartherapies.com/investor-relations
Company Research
Source: GlobeNewswire
NEW YORK, June 13, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced data presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience held virtually June 10-12, 2022. Three posters were presented on Saturday June 11, 2022 during the “In the Spotlight: Live Posters 2” session: Oral Poster titled “Lumateperone (ITI-007) in the Treatment of Bipolar Depression: Efficacy Across Symptoms” Oral Poster titled “Effect of Lumateperone (ITI-007) on Quality of Life and Functional Disability in the Treatment of Bipolar Depression” Oral Poster titled “Metabolic Syndrome in Bipolar Depression with Lumateperone (ITI-007): A Post Hoc Analysis of 2 Randomized, Placebo-Controlled Trials” “At ISBD, we shared additional analyses from our lumateperone bipolar depression program including findings con
Show less
Read more
Impact Snapshot
Event Time:
ITCI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ITCI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ITCI alerts
High impacting Intra-Cellular Therapies Inc. news events
Weekly update
A roundup of the hottest topics
ITCI
News
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Needham & Company LLC from $82.00 to $90.00. They now have a "buy" rating on the stock.MarketBeat
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Mizuho from $82.00 to $96.00. They now have a "buy" rating on the stock.MarketBeat
- Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success [Yahoo! Finance]Yahoo! Finance
- Intra-Cellular Therapies drops 2%, prices $500M equity financing [Seeking Alpha]Seeking Alpha
- Intra-Cellular Therapies Prices Public Offering of Common StockGlobeNewswire
ITCI
Earnings
- 2/22/24 - Beat
ITCI
Sec Filings
- 4/18/24 - Form 8-K
- 4/18/24 - Form 424B5
- 4/16/24 - Form 8-K
- ITCI's page on the SEC website